Here, fu is cell fraction unaffected by treatment, and D is mean peak concentration (Cmax) reported in plasma (Laneuville P. et al J Clin Oncol 28:e169-71). IPP and IC50 values for each Ba/F3 BCR-ABL mutant were compared with previously reported CCyR rates for nilotinib (Kantarjian H. et al Blood 110:3540-6) and dasatinib (Muller M.C. et al Blood 114:4944-53). Consistent with the particularly negative effect of P-loop mutations on drug binding and clinical outcome with imatinib, we found that 4 of 7 these mutations tested (G250E, Y253H, E255K, E255V) showed lower dose-response slope relative to wild-type BCR-ABL in addition to high IC50, while all other mutations showed variably increased slopes. Furthermore, the range of IPPs of imatinib for these mutations was lower than (and not overlapping with) all other mutations (0.084–1.66 vs 2.93–5.59; p=6*10−6). Slope variability provided particular additional interpretive value in cases where in vitro IC50 and clinical response are disparate. For example, G250E and V379I mutants feature comparable cellular IC50 values for imatinib (1184 and 1140 nM, respectively), but only G250E harbors worse clinical prognosis, arguably due to a lower dose-response slope of G250E, as also reflected in a lower IPP value compared to V379I (1.66 vs 3.04). Similarly, the M244V mutant does not confer substantial clinical resistance to imatinib despite increased IC50, possibly due to an exceptionally high slope value (m=5 vs. m=1.87 for wild-type BCR-ABL) reflecting a very steep dose-response curve which may render patients with this mutation particularly vulnerable to consequences of unfavorable imatinib pharmacokinetic profile or reduced compliance. Lastly, we examined whether higher IPP values were predictive of better clinical response to nilotinib and dasatinib in second-line clinical setting. Dasatinib-treated patients with mutations resulting in high IPP (IPP>7) had a significantly higher mean CCyR rate than those patients with lower IPPs (53% vs 31%; p=0.038). In contrast, this relationship was not evident when IC50 alone was used. In nilotinib-treated patients the difference in mean CCyR rate between patients with values above or below the median IPP or IC50 value approached but did not reach statistical significance (p=0.055 for both cases), potentially due to the lower number of patients for which response data by mutation has been reported (7 vs 11 mutations, 65 vs 295 patients with mutations, for nilotinib and dasatinib respectively). Taken together, our data suggest an integrated metric such as IPP may have both further relevance in conjunction with individual pharmacokinetic measurements and application to improved interpretation of mutationally-guided TKI treatment selection in CML and other malignancies.
Vainstein:Neumedicines Inc: Employment. Druker:MolecularMD: OHSU and Dr. Druker have a financial interest in MolecularMD. Dr Druker is a scientific founder, consultant, and stock holder in MolecularMD. OHSU has licensed technology used in some of these clinical trials to MolecularMD., OHSU and Dr. Druker have a financial interest in MolecularMD. Dr Druker is a scientific founder, consultant, and stock holder in MolecularMD. OHSU has licensed technology used in some of these clinical trials to MolecularMD. Other; Novartis, Bristol-Myers Squibb: Dr Druker's institution has contracts with these companies to pay for patient costs, nurse and data manager salaries, and institutional overhead. Dr Druker does not derive salary, nor does his lab receive funds from these contracts. Other.
Asterisk with author names denotes non-ASH members.